Alpha fetoprotein targeted T-cell therapy - Adaptimmune

Drug Profile

Alpha fetoprotein targeted T-cell therapy - Adaptimmune

Alternative Names: AFP SPEAR T-cell therapy; AFP TCR - Adaptimmune; AFPᶜ³³²T cell therapy - Adaptimmune; Autologous genetically modified AFPᶜ³³² T-cells - Adaptimmune

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adaptimmune
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma

Most Recent Events

  • 01 May 2017 Phase-I clinical trials in Hepatocellular carcinoma (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in USA (IV) (NCT03132792)
  • 13 Mar 2017 Adaptimmune Therapeutics files for patent protection with patent co-operation treaty for AFP SPEAR T-cell therapy before March 2017
  • 13 Mar 2017 Adaptimmune Therapeutics has patents pending for AFP SPEAR T-cell therapy in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top